CR20210442A - ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214) - Google Patents

ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214)

Info

Publication number
CR20210442A
CR20210442A CR20210442A CR20210442A CR20210442A CR 20210442 A CR20210442 A CR 20210442A CR 20210442 A CR20210442 A CR 20210442A CR 20210442 A CR20210442 A CR 20210442A CR 20210442 A CR20210442 A CR 20210442A
Authority
CR
Costa Rica
Prior art keywords
pi3k
hydroxy groups
imidazole derivatives
derivatives substituted
gamma inhibitors
Prior art date
Application number
CR20210442A
Other languages
English (en)
Inventor
Nikoo Falahatpisheh
Richard B Sparks
Andrew W Buesking
Andrew P Combs
Padmaja Polam
Daniel Levy
Artem Shvartsbart
David M Burns
Brent Douty
Ravi Kumar Jalluri
Eddy W Yue
Stacey Shepard
Lixin Shao
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of CR20210442A publication Critical patent/CR20210442A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente invención se refiere a compuestos de Fórmula (I): o sales de los mismos farmacéuticamente aceptables, los cuales son inhibidores de PI3K-y los cuales son útiles para el tratamiento de trastornos tales como enfermedades autoinmunes, cáncer, enfermedades cardiovasculares, y enfermedades neurodegenerativas.
CR20210442A 2017-10-18 2018-10-17 ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214) CR20210442A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762574057P 2017-10-18 2017-10-18
US201762608897P 2017-12-21 2017-12-21
US201862727316P 2018-09-05 2018-09-05
PCT/US2018/056311 WO2019079469A1 (en) 2017-10-18 2018-10-17 CONDENSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH HYDROXY TERTIARY GROUPS AS INHIBITORS OF PI3K-GAMMA

Publications (1)

Publication Number Publication Date
CR20210442A true CR20210442A (es) 2021-12-20

Family

ID=64110207

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20200214A CR20200214A (es) 2017-10-18 2018-10-17 ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
CR20210442A CR20210442A (es) 2017-10-18 2018-10-17 ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y (Divisional Exp. 2020-0214)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20200214A CR20200214A (es) 2017-10-18 2018-10-17 ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y

Country Status (32)

Country Link
US (3) US10738057B2 (es)
EP (2) EP3697789B1 (es)
JP (2) JP7244504B2 (es)
KR (1) KR20200089264A (es)
CN (1) CN111542526B (es)
AU (2) AU2018350980B2 (es)
BR (1) BR112020007593A2 (es)
CA (1) CA3084589A1 (es)
CL (1) CL2020001047A1 (es)
CR (2) CR20200214A (es)
CY (1) CY1124814T1 (es)
EC (1) ECSP20024651A (es)
ES (1) ES2902390T3 (es)
GE (1) GEP20237483B (es)
HR (1) HRP20211827T1 (es)
HU (1) HUE056615T2 (es)
IL (3) IL295978B1 (es)
JO (1) JOP20200086A1 (es)
LT (1) LT3697789T (es)
MA (1) MA50398B1 (es)
MD (1) MD3697789T2 (es)
MX (1) MX2020003862A (es)
PE (1) PE20210169A1 (es)
PH (1) PH12020550442A1 (es)
PL (1) PL3697789T3 (es)
PT (1) PT3697789T (es)
RS (1) RS62818B1 (es)
SG (1) SG11202003428VA (es)
SI (1) SI3697789T1 (es)
TW (1) TWI803525B (es)
WO (1) WO2019079469A1 (es)
ZA (1) ZA202201220B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200214A (es) 2017-10-18 2020-07-25 Incyte Corp ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
WO2019126121A1 (en) 2017-12-19 2019-06-27 Tp Therapeutics, Inc. Macrocyclic compounds for treating disease
TWI827583B (zh) * 2018-03-08 2024-01-01 美商英塞特公司 作為ＰＩ３Ｋ-γ抑制劑之胺基吡嗪二醇化合物
SG11202013216RA (en) 2018-07-05 2021-01-28 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
BR112021004094A2 (pt) * 2018-09-05 2021-05-25 Incyte Corporation formas cristalinas de um inibidor de fosfoinositídeo 3-quinase (pi3k)
CN115286521B (zh) * 2022-07-11 2023-11-03 上海医药集团(本溪)北方药业有限公司 一种盐酸左沙丁胺醇的合成方法

Family Cites Families (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4269846A (en) 1979-10-29 1981-05-26 Usv Pharmaceutical Corporation Heterocyclic compounds useful as anti-allergy agents
US5137876A (en) 1990-10-12 1992-08-11 Merck & Co., Inc. Nucleoside antiviral and anti-inflammatory compounds and compositions and methods for using same
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
PT1107964E (pt) 1998-08-11 2010-06-11 Novartis Ag Derivados de isoquinolina com actividade inibidora da angiogénese
US6133031A (en) 1999-08-19 2000-10-17 Isis Pharmaceuticals Inc. Antisense inhibition of focal adhesion kinase expression
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0011092D0 (en) 2000-05-08 2000-06-28 Black James Foundation Gastrin and cholecystokinin receptor ligands (III)
AU1560802A (en) 2000-06-28 2002-01-08 Smithkline Beecham Plc Wet milling process
ATE420879T1 (de) 2001-09-19 2009-01-15 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
FR2831536A1 (fr) 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
CA2465247C (en) 2001-10-26 2010-05-18 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
PL211461B1 (pl) 2001-10-30 2012-05-31 Dana Farber Cancer Inst Inc Zastosowanie pochodnych staurosporyny do wytwarzania kompozycji farmaceutycznej do leczenia lub zapobiegania białaczkom i zespołom mielodysplastycznym, preparat farmaceutyczny do leczenia białaczek i zestaw farmaceutyczny
DE10207843A1 (de) 2002-02-15 2003-09-04 Schering Ag Mikrolia-Inhibitoren zur Unterbrechung von Interleukin 12 und IFN-gamma vermittelten Immunreaktionen
TW200406374A (en) 2002-05-29 2004-05-01 Novartis Ag Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
AR042052A1 (es) 2002-11-15 2005-06-08 Vertex Pharma Diaminotriazoles utiles como inhibidores de proteinquinasas
UA80767C2 (en) 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7157460B2 (en) 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
EP1599474B1 (en) 2003-03-04 2013-04-24 California Institute Of Technology Heterocyclic oligomeric compounds for DNA recognition
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
PE20050952A1 (es) 2003-09-24 2005-12-19 Novartis Ag Derivados de isoquinolina como inhibidores de b-raf
AU2004282219C1 (en) * 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
WO2005118580A2 (en) 2004-05-12 2005-12-15 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Tricyclic compounds as inhibitors of the hypoxic signaling pathway
MY144044A (en) 2004-06-10 2011-07-29 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1885352A2 (en) 2004-11-24 2008-02-13 Novartis AG Combinations comprising jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
AU2006278396A1 (en) 2005-08-04 2007-02-15 Sirtris Pharmaceuticals, Inc. Benzimidazole derivatives as sirtuin modulators
WO2007028051A2 (en) 2005-09-02 2007-03-08 Abbott Laboratories Novel imidazo based heterocycles
ATE456565T1 (de) 2006-06-22 2010-02-15 Biovitrum Ab Publ Pyridin- und pyrazinderivate als mnk- kinaseinhibitoren
US20090131481A1 (en) 2007-03-27 2009-05-21 Paratek Pharmaceuticals, Inc. Transcription Factor Modulating Compounds and Methods of Use Thereof
DE102007035333A1 (de) 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
EP2220068B1 (en) 2007-11-16 2016-01-27 Incyte Holdings Corporation 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
CA2709883A1 (en) 2007-12-19 2009-06-25 The Scripps Research Institute Benzimidazoles and analogs as rho kinase inhibitors
AP2010005308A0 (en) 2008-01-15 2010-06-30 Siga Technologies Inc Antiviral drugs for treatment of arenavirus infection
WO2009108546A1 (en) 2008-02-26 2009-09-03 Merck & Co., Inc. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
PT2288610T (pt) 2008-03-11 2016-10-17 Incyte Holdings Corp Derivados de azetidina e de ciclobutano como inibidores de jak
WO2009133127A1 (en) 2008-04-30 2009-11-05 Merck Serono S.A. Fused bicyclic compounds and use thereof as pi3k inhibitors
WO2009158118A2 (en) 2008-05-30 2009-12-30 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
WO2010051245A1 (en) 2008-11-03 2010-05-06 Merck Sharp & Dohme Corp. Benzimidazole and aza-benzimidazole carboxamides
WO2010061903A1 (ja) 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
JP2012519177A (ja) 2009-02-27 2012-08-23 バーテックス ファーマシューティカルズ インコーポレイテッド 三環式ピラゾロピリジンキナーゼインヒビター
KR20120034613A (ko) * 2009-04-16 2012-04-12 센트로 내셔널 드 인베스티가시오네스 온콜로지카스 (씨엔아이오) 키나아제 억제제로서 사용을 위한 이미다조피라진
EP2432555B1 (en) 2009-05-22 2014-04-30 Incyte Corporation N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
US9249145B2 (en) 2009-09-01 2016-02-02 Incyte Holdings Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
US8680108B2 (en) 2009-12-18 2014-03-25 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
WO2011099832A2 (en) 2010-02-12 2011-08-18 Crystalgenomics, Inc. Novel benzimidazole compound, preparation method thereof and pharmaceutical composition comprising the same
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
MX364636B (es) 2010-03-10 2019-05-03 Incyte Corp Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1).
WO2011123609A1 (en) 2010-03-31 2011-10-06 Glaxo Group Limited Imidazolyl-imidazoles as kinase inhibitors
WO2011130342A1 (en) 2010-04-14 2011-10-20 Incyte Corporation FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS
US8877707B2 (en) 2010-05-24 2014-11-04 Presidio Pharmaceuticals, Inc. Inhibitors of HCV NS5A
US8623857B2 (en) 2010-05-26 2014-01-07 Merck Sharp & Dohme Corp. N-phenyl imidazole carboxamide inhibitors of 3-phosphoinositide-dependent protein kinase-1
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
PE20141044A1 (es) 2010-10-13 2014-09-07 Millennium Pharm Inc Heteroarilos y sus usos
JP5917544B2 (ja) 2010-11-19 2016-05-18 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｊａｋ阻害剤としての複素環置換ピロロピリジンおよびピロロピリミジン
AU2011329734B2 (en) 2010-11-19 2015-05-28 Incyte Holdings Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
UY33756A (es) 2010-11-30 2012-06-29 Takeda Pharmaceutical Compuesto biciclico
WO2012087881A1 (en) 2010-12-20 2012-06-28 Incyte Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US8673905B2 (en) 2011-03-17 2014-03-18 Hoffmann-La Roche Inc. Imidazo pyrazines
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
US9029389B2 (en) 2011-04-21 2015-05-12 Institut Pasteur Korea Anti-inflammation compounds
CA2836487A1 (en) 2011-06-09 2012-12-13 Rhizen Pharmaceuticals Sa Novel compounds as modulators of gpr-119
KR20140040819A (ko) 2011-06-20 2014-04-03 인사이트 코포레이션 Ｊａｋ 저해제로서의 아제티디닐 페닐, 피리딜 또는 피라지닐 카르복스아미드 유도체
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
PE20181272A1 (es) 2011-09-02 2018-08-03 Incyte Holdings Corp Heterociclilaminas como inhibidores de pi3k
JP6088542B2 (ja) * 2012-01-10 2017-03-01 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔキナーゼ阻害剤としての置換イミダゾピラジン類
WO2013129674A1 (ja) 2012-03-01 2013-09-06 学校法人兵庫医科大学 新規ベンズイミダゾール誘導体及びその用途
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
WO2013180193A1 (ja) 2012-05-31 2013-12-05 住友化学株式会社 縮合複素環化合物
CA2877550C (en) 2012-07-13 2020-09-08 Ucb Biopharma Sprl Imidazopyridine derivatives as modulators of tnf activity
SG10201703533VA (en) 2012-11-01 2017-06-29 Incyte Corp Tricyclic fused thiophene derivatives as jak inhibitors
TW202333734A (zh) 2013-03-01 2023-09-01 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
US8999992B2 (en) 2013-03-15 2015-04-07 Vm Pharma Llc Crystalline forms of tryosine kinase inhibitors and their salts
WO2014149207A2 (en) 2013-03-15 2014-09-25 Dow Agrosciences Llc Benzimidazole-based insecticidal compositions and related methods
WO2014153529A1 (en) 2013-03-22 2014-09-25 The Scripps Research Institute Substituted benzimidazoles as nociceptin receptor modulators
WO2014182954A1 (en) 2013-05-08 2014-11-13 Colorado Seminary, Which Owns And Operates The University Of Denver Antibiotic and anti-parasitic agents that modulate class ii fructose 1,6-bisphosphate aldolase
FI3786162T3 (fi) 2013-05-17 2023-10-02 Incyte Holdings Corp Bipyratsolijohdannaisia jak-inhibiittoreina
SG10201800325PA (en) 2013-07-17 2018-02-27 Otsuka Pharma Co Ltd Cyanotriazole compounds
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3795152A1 (en) 2014-04-08 2021-03-24 Incyte Corporation Treatment of b-cell malignancies by a combination jak and pi3k inhibitor
EP2930048A1 (en) 2014-04-10 2015-10-14 Johnson Controls Automotive Electronics SAS Head up display projecting visual information onto a screen
US10077277B2 (en) 2014-06-11 2018-09-18 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors
CA2961525A1 (en) 2014-09-16 2016-03-24 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10214537B2 (en) * 2014-10-22 2019-02-26 Bristol-Myers Squibb Company Bicyclic heteroaryl amine compounds
WO2016064958A1 (en) * 2014-10-22 2016-04-28 Bristol-Myers Squibb Company Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
WO2016106624A1 (en) * 2014-12-31 2016-07-07 Merck Sharp & Dohme Corp. Tertiary alcohol imidazopyrazine btk inhibitors
US9586949B2 (en) 2015-02-09 2017-03-07 Incyte Corporation Aza-heteroaryl compounds as PI3K-gamma inhibitors
US9968604B2 (en) * 2015-04-16 2018-05-15 Chiesi Farmaceutici S.P.A. Chromene derivatives as phoshoinositide 3-kinases inhibitors
KR20180003614A (ko) 2015-05-12 2018-01-09 카리라 파마슈티컬스, 아이앤씨. 바이사이클릭 화합물
WO2017079519A1 (en) 2015-11-06 2017-05-11 Incyte Corporation Heterocyclic compounds as pi3k-gamma inhibitors
MA54567A (fr) 2016-01-05 2021-10-27 Incyte Corp Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
WO2017223414A1 (en) * 2016-06-24 2017-12-28 Incyte Corporation HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS
CN109937038A (zh) 2016-08-26 2019-06-25 田边三菱制药株式会社 双环式含氮杂环化合物
US20200000713A1 (en) 2017-01-20 2020-01-02 Massachusetts Institute Of Technology Injectable polymer micro-depots for controlled local drug delivery
TWI674261B (zh) 2017-02-17 2019-10-11 美商英能腫瘤免疫股份有限公司 Nlrp3 調節劑
CN117143042A (zh) 2017-07-24 2023-12-01 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
US10988454B2 (en) 2017-09-14 2021-04-27 Abbvie Overseas S.À.R.L. Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use
IL301746A (en) 2017-10-18 2023-05-01 Epizyme Inc Amine-Disubstituted Heterocyclic Compounds as EHMT2 Inhibitors, Their Salts, and Method for Their Synthesis
CR20200214A (es) 2017-10-18 2020-07-25 Incyte Corp ALCOHOLES TERCIARIOS COMO INHIBIDORES DE PI3K-y
WO2019126121A1 (en) 2017-12-19 2019-06-27 Tp Therapeutics, Inc. Macrocyclic compounds for treating disease
UA127604C2 (uk) 2017-12-21 2023-11-01 Басф Се Пестицидні сполуки
FI3728254T3 (fi) 2017-12-21 2023-05-05 Boehringer Ingelheim Int Bentsyyliaminosubstituoidut pyridopyrimidinonit ja johdannaiset SOS1-estäjinä
BR112021004094A2 (pt) 2018-09-05 2021-05-25 Incyte Corporation formas cristalinas de um inibidor de fosfoinositídeo 3-quinase (pi3k)

Also Published As

Publication number Publication date
JOP20200086A1 (ar) 2020-04-30
CL2020001047A1 (es) 2020-08-28
EP4006034A1 (en) 2022-06-01
MA50398A (fr) 2021-05-05
AU2023203088A1 (en) 2023-06-15
RS62818B1 (sr) 2022-02-28
GEP20237483B (en) 2023-03-27
MX2020003862A (es) 2020-08-13
CN111542526A (zh) 2020-08-14
SG11202003428VA (en) 2020-05-28
IL273983A (en) 2020-05-31
CR20200214A (es) 2020-07-25
ECSP20024651A (es) 2020-06-30
IL295978B2 (en) 2024-01-01
ZA202201220B (en) 2023-03-29
HRP20211827T1 (hr) 2022-03-18
PL3697789T3 (pl) 2022-02-21
EP3697789B1 (en) 2021-09-29
IL273983B (en) 2022-10-01
JP2021500340A (ja) 2021-01-07
US11225486B2 (en) 2022-01-18
US20200385392A1 (en) 2020-12-10
KR20200089264A (ko) 2020-07-24
IL273983B2 (en) 2023-02-01
CY1124814T1 (el) 2022-11-25
TWI803525B (zh) 2023-06-01
TW201927788A (zh) 2019-07-16
BR112020007593A2 (pt) 2020-09-24
PH12020550442A1 (en) 2021-05-31
CA3084589A1 (en) 2019-04-25
AU2018350980B2 (en) 2023-02-23
PE20210169A1 (es) 2021-01-29
TW202340200A (zh) 2023-10-16
IL295978A (en) 2022-10-01
US20220213107A1 (en) 2022-07-07
LT3697789T (lt) 2021-12-10
EP3697789A1 (en) 2020-08-26
US20190152975A1 (en) 2019-05-23
IL295978B1 (en) 2023-09-01
SI3697789T1 (sl) 2022-04-29
JP7244504B2 (ja) 2023-03-22
AU2018350980A1 (en) 2020-04-30
US11926630B2 (en) 2024-03-12
JP2023085290A (ja) 2023-06-20
CN111542526B (zh) 2024-01-09
US10738057B2 (en) 2020-08-11
WO2019079469A1 (en) 2019-04-25
MA50398B1 (fr) 2021-10-29
MD3697789T2 (ro) 2022-02-28
HUE056615T2 (hu) 2022-02-28
ES2902390T3 (es) 2022-03-28
PT3697789T (pt) 2021-12-31

Similar Documents

Publication Publication Date Title
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12020550442A1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12019500214A1 (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
PH12019500480A1 (en) Pyridine compound
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
PH12020551390A1 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MD20160116A2 (ro) Inhibitori spirociclici substituiţi ai autotaxinei
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
PH12019502363A1 (en) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
EA033236B1 (ru) Новые производные пиразола в качестве ингибиторов nik
PH12017500007A1 (en) Quinolizinone derivatives as p13k inhibitors
MX2019000982A (es) Compuestos y composiciones y usos de los mismos.
PH12017501134A1 (en) Fumagillol derivatives
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
EA202092082A1 (ru) Соединения аминопиразиндиола как ингибиторы pi3k-
GB2553685A (en) Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis